Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. / the EACS Governing Board.
I: HIV Medicine, Bind 19, Nr. 5, 2018, s. 309-315.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0
AU - Ryom, L.
AU - Boesecke, C.
AU - Bracchi, M.
AU - Ambrosioni, J.
AU - Pozniak, A.
AU - Arribas, J.
AU - Behrens, G.
AU - Mallon, P. G.M.
AU - Puoti, M.
AU - Rauch, A.
AU - Miro, J. M.
AU - Kirk, O.
AU - Marzolini, C.
AU - Lundgren, J. D.
AU - Battegay, M.
AU - d'Arminio Monforte, Antonella
AU - Clumeck, Nathan
AU - Dedes, Nikos
AU - Gatell, José M.
AU - Horban, Andrzej
AU - Katlama, Christine
AU - McCormack, Sheena
AU - Molina, Jean Michel
AU - Mussini, Cristina
AU - Raffi, François
AU - Reiss, Peter
AU - Stellbrink, Hans Jürgen
AU - Bower, Mark
AU - Cinque, Paola
AU - Collins, Simon
AU - Compston, Juliet
AU - De Wit, Stéphane
AU - Fabbri, Leonardo M.
AU - Fux, Christoph A.
AU - Guaraldi, Giovanni
AU - Martínez, Esteban
AU - Papapoulos, Socrates
AU - du Pasquier, Renaud
AU - Poulter, Neil
AU - Williams, Ian
AU - Winston, Alan
AU - Berenguer, Juan
AU - Bhagani, Sanjay
AU - Bruno, Raffaele
AU - Konov, Svilen
AU - Lacombe, Karine
AU - Mauss, Stefan
AU - Mendão, Luís
AU - Peters, Lars
AU - Rockstroh, Jürgen K.
AU - the EACS Governing Board
PY - 2018
Y1 - 2018
N2 - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.
AB - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.
KW - antiretroviral treatment
KW - ART
KW - coinfections
KW - comorbidities
KW - European AIDS Clinical Society guidelines
KW - HBV
KW - HCV
KW - HIV
KW - opportunistic diseases
U2 - 10.1111/hiv.12600
DO - 10.1111/hiv.12600
M3 - Journal article
C2 - 29493093
AN - SCOPUS:85045475030
VL - 19
SP - 309
EP - 315
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 5
ER -
ID: 214513773